Albumin–Bilirubin Grade and HIV Status in Hepatocellular Carcinoma as Predictors of Survival in Zimbabwe
Livers · 09.06.2026 · 6 (3) · 49
DOI: 10.3390/livers6030049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Livers, online erschienen am 09.06.2026. Verfasst von Tinashe A. Mazhindu und 8 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Association for Cancer Research, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Background
Infection with HIV increases the risk of developing hepatocellular carcinoma, and the albumin–bilirubin grade assesses liver function and has been shown to be prognostic. We evaluated the albumin–bilirubin score/grade and the HIV status of hepatocellular carcinoma patients in Zimbabwe and explored the impact on median survival.
Methods
A 10-year retrospective observational study of hepatocellular carcinoma patients was conducted at a single tertiary-level cancer center in Harare, Zimbabwe. Survival probabilities were estimated using the Kaplan–Meier method, and differences between groups were compared using the log-rank test and Cox proportional hazards regression.
Results
A total of 95 participants were evaluated, of whom 72.6% were male. Most HCC cases were diagnosed using imaging and serum alpha-fetoprotein, with 59% presenting at Barcelona Clinic Liver Cancer stage C or D. Compared with patients who were HIV-negative, patients who were HIV-positive (OR 2.2; 95% CI 1.54–5.26, p = 0.0008) or had an unknown HIV status (OR 4.2; 95% CI 2.2–8; p < 0.0001) had higher odds of being at ALBI grade 3 at the time of HCC diagnosis. ALBI grade 1 patients had better median survival compared to grade 2 and 3 patients, though this result was statistically insignificant (grade 2: HR = 1.45, 95% CI: 0.30–7.13; grade 3: HR = 1.47, 95% CI: 0.28–7.60). Regarding HIV status, median survival was 2.4 months for HIV-positive patients and 2.6 months for HIV-negative patients (p = 0.51); HIV positivity was not significantly associated with median survival (HR = 1.50, 95% CI: 0.46–4.91). Only 30.5% of patients received cancer therapy, all of which was palliative, with no observed survival benefit.
Conclusions
The majority of hepatocellular carcinoma patients in Zimbabwe were diagnosed at an advanced stage, with hepatitis B or C viral infections and alcohol consumption identified as primary risk factors. Median survival rates were low. Neither HIV infection nor ALBI score grading had a significant impact on median survival.
Förderung
- American Association for Cancer Research
- Bill and Melinda Gates Foundation
Zitieren
APA
Mazhindu, T. A., Nyangwara, V., Montaño, M. A., Matsikidze, E., Chihaka, O., Jang, C., Borok, M. Z., Masimirembwa, C., & Ndlovu, N. (2026). Albumin–Bilirubin Grade and HIV Status in Hepatocellular Carcinoma as Predictors of Survival in Zimbabwe. Livers, 6(3), 49. https://doi.org/10.3390/livers6030049
Vancouver
Mazhindu TA, Nyangwara V, Montaño MA, Matsikidze E, Chihaka O, Jang C, et al. Albumin–Bilirubin Grade and HIV Status in Hepatocellular Carcinoma as Predictors of Survival in Zimbabwe. Livers. 2026;6(3):49. doi:10.3390/livers6030049
BibTeX
@article{Mazhindu2026,
author = {Mazhindu, Tinashe A. and Nyangwara, Vincent and Montaño, Michalina A. and Matsikidze, Edith and Chihaka, Onesai and Jang, Charley and Borok, Margaret Z. and Masimirembwa, Collen and Ndlovu, Ntokozo},
title = {Albumin–Bilirubin Grade and HIV Status in Hepatocellular Carcinoma as Predictors of Survival in Zimbabwe},
journal = {Livers},
year = {2026},
volume = {6},
number = {3},
pages = {49},
doi = {10.3390/livers6030049}
}
EUVIMED